We use cookies for a better user experience. Read our Privacy Policy
I Agree
Cardiovascular Drugs Market
Cardiovascular diseases (CVDs) comprise disorders and conditions related to circulatory system which include heart and vascular system. The global cardiovascular drugs market was valued approximately US$ 80.0 Bn in 2016 and is anticipated to register CAGR of over 1.0% from 2017 to 2025 to reach value of approximately US$ 91.0 Bn by 2025. Drug classes used to treat cardiovascular indications such as hyperlipidemia, hypertension are likely to fuel expansion of the global cardiovascular drugs market from 2017 to 2025.
Cardiovascular diseases are one of the leading causes of death worldwide. According to American Heart Association, in 2015, approximately 41.5% of the U.S. population was suffering from some form of cardiovascular disease, it is further estimated that this prevalence is likely to increase to 45% by 2035. Sedentary lifestyle, changing dietary habits and surge in associated risk factors are likely to increase the number of patients with cardiovascular diseases. According to the Centers for Disease Control and Prevention (CDC) of the U.S., high blood pressure, high cholesterol, and smoking are key risk factors for heart disease. About half of the population of the U.S. (47%) have at least one of these three risk factors. To treat the diseases, key players are investing in to develop new drugs with better efficacy and less side effects. Launch of PCSK9 inhibitors (Praluent) for treating hyperlipidemia in 2016 is likely to fuel expansion of anti-hyperlipidemia drugs market segment by 2025 augmenting global cardiovascular drugs market. However, recent expiry of patent exclusivity of blockbuster cardiovascular drugs has led to plethora of generic drugs which is likely to hamper global cardiovascular drugs market.
There are many unmet needs in global cardiovascular drugs market which create huge opportunities for existing players and new entrants in global market. Biologics provide ample opportunities for players operating in the global cardiovascular drugs market. Recent developments in biologic cardiovascular drugs such as Pfizer’s PCSK9 inhibitor, Esperion Therapeutics’ novel LDL-lowering drug ETC-1002 and Merck’s CETP inhibitor anacetrapib, uncovers the potential of these drugs. Blockbuster drugs are losing their patent exclusivity which has set a trend to introduce generics in market by local as well as international players. For instance, Crestor launched by Astrazeneca and indicated for the treatment of hyperlipidemia, lost patent in early 2016 and in April 2016, the U.S. FDA approved first generic to this drug to Watson Pharmaceuticals Inc.
The global cardiovascular drugs market has been segmented on the basis of drug class, indication, distribution channel and geography. Among drug class, anti-clotting agents segment is projected to lead the market and is expected to continue its dominance during the forecast period followed by anti-hyperlipidemia segment. Introduction of new anti-hyperlipidemia drug such as PCSK9 Inhibitor (Praluent) and increasing incidences of hyperlipidemia is likely to propel expansion of the segment. Among indications, hypertension was the leading revenue generating segment in 2016 and it is likely to continue its dominance during the forecast period. Arrhythmia segment of indication is likely to lose its market share during the forecast period owing to shift of preference from anti-arrhythmia drugs to advanced implantable cardiovascular devices such as pacemakers. Among various distribution channels, retail pharmacies was the leading distribution channel in 2016 and is likely to account for leading share during the forecast period.
Geographically, North America captured lion’s share of global cardiovascular drugs market in 2016. However increasing adoption of generics in the U.S. is key concern area among key players. Asia Pacific market is projected to gain market share during the forecast period and is likely to be key revenue generator in the coming years. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and incentives for generic production in countries such as Brazil, South Africa, Saudi Arabia, etc. is likely to boost market growth in Latin America and Middle East & Africa.
Key companies operating in the global cardiovascular drugs market and profiled in the report include AstraZeneca plc., Bayer AG, Merck & Co., Inc., Sanofi, Pfizer, Inc., Eli Lilly & Company among others. These players are adopting organic and in-organic growth strategies to expand their product offerings, strengthen their geographical reach, increase customer base and garner market share. For instance, in December 2015, AstraZeneca acquired ZS pharma which added pipeline biological drug for chronic heart failure to AstraZeneca’s existing cardiovascular drugs pipeline. In another instance, in 2016, Sanofi launched new cardiovascular drug Praluent for treatment of hyperlipidemia.
Alarming Rise in the Cases of Cardiovascular Diseases and Disorders to Propel the Growth Opportunities across the Cardiovascular Drugs Market
Cases related to cardiovascular disorders and diseases have increase manifold over the years. The growing prevalence of cardiovascular diseases has resulted in the formation of novel drugs and formulations for rapid treatment. The growing demand for such products will bring immense growth opportunities for the cardiovascular drugs market during the assessment period of 2017-2025.
The global cardiovascular drugs market has been segmented as follows:
|
Drug Class |
|
|
Indication |
|
|
Distribution Channel |
|
|
Geography |
|
Interested in this report?
Get a FREE Brochure now!
*Get Brochure Report (PDF) sent to your email within minutes
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global CVD Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Developments
4.2. Overview
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.5. Global CVD Market Analysis and Forecasts, 2015–2025
4.5.3. Market Revenue Projections (US$ Mn)
4.6. CVD Market - Global Supply Demand Scenario
4.7. Porter’s Five Force Analysis
4.9. Market Outlook
5. Global CVD Market Analysis and Forecasts, By Drug Class
5.1. Introduction & Definition
5.2. Key Findings
5.4. Market Value Forecast By Drug Class , 2015–2025
5.4.1. Renin-Angiotensin System Blockers
5.4.1.1. ACE Inhibitors
5.4.1.2. Angiotensin Receptor Blockers
5.4.2. Beta Blockers
5.4.3. Diuretics
5.4.4. Anti-Clotting Agents
5.4.4.1. Anti-Coagulants
5.4.4.2. Platelet Aggregation Inhibitors
5.4.5. Antihyperlipidemics
5.4.6. Other Antihypertensives
5.4.7. Calcium Channel Blockers
5.4.8. Others
5.5. Market Attractiveness By Drug Class
6. Global CVD Market Analysis and Forecasts, By Indications
6.1. Introduction & Definition
6.2. Key Findings
6.4. Market Value Forecast By Indications , 2015–2025
6.4.1. Hypertension
6.4.2. Hyperlipidemia
6.4.3. Coronary Artery Disease
6.4.4. Peripheral Artery Disease
6.4.5. Arrhythmia
6.4.6. Others
6.5. Market Attractiveness By Indications
7. Global CVD Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings
7.4. Market Value Forecast By Distribution Channel , 2015–2025
7.4.1. Hospital Pharmacy
7.4.2. Retail Pharmacy
7.4.3. Online Pharmacy
7.5. Market Attractiveness By Distribution Channel
8. Global CVD Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Country/Region
9. North America CVD Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Drug Class , 2015–2025
9.2.1. Renin-Angiotensin System Blockers
9.2.1.1. ACE Inhibitors
9.2.1.2. Angiotensin Receptor Blockers
9.2.2. Beta Blockers
9.2.3. Diuretics
9.2.4. Anti-Clotting Agents
9.2.4.1. Anti-Coagulants
9.2.4.2. Platelet Aggregation Inhibitors
9.2.5. Antihyperlipidemics
9.2.6. Other Antihypertensives
9.2.7. Calcium Channel Blockers
9.2.8. Others
9.3. Market Value Forecast By Indications , 2015–2025
9.3.1. Hypertension
9.3.2. Hyperlipidemia
9.3.3. Coronary Artery Disease
9.3.4. Peripheral Artery Disease
9.3.5. Arrhythmia
9.3.6. Others
9.4. Market Value Forecast By Distribution Channel , 2015–2025
9.4.1. Hospital Pharmacy
9.4.2. Retail Pharmacy
9.4.3. Online Pharmacy
9.5. Market Value Forecast By Country , 2015–2025
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Class
9.6.2. By Indications
9.6.3. By Distribution Channel
9.6.4. By Country
10. Europe CVD Market Analysis and Forecast
10.1.Introduction
10.1.1. Key Findings
10.2.Market Value Forecast By Drug Class , 2015–2025
10.2.1. Renin-Angiotensin System Blockers
10.2.1.1. ACE Inhibitors
10.2.1.2. Angiotensin Receptor Blockers
10.2.2. Beta Blockers
10.2.3. Diuretics
10.2.4. Anti-Clotting Agents
10.2.4.1. Anti-Coagulants
10.2.4.2. Platelet Aggregation Inhibitors
10.2.5. Antihyperlipidemics
10.2.6. Other Antihypertensives
10.2.7. Calcium Channel Blockers
10.2.8. Others
10.3. Market Value Forecast By Indications , 2015–2025
10.3.1. Hypertension
10.3.2. Hyperlipidemia
10.3.3. Coronary Artery Disease
10.3.4. Peripheral Artery Disease
10.3.5. Arrhythmia
10.3.6. Others
10.4. Market Value Forecast By Distribution Channel , 2015–2025
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy
10.4.3. Online Pharmacy
10.5. Market Value Forecast By Country , 2015–2025
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Indications
10.6.3. By Distribution Channel
10.6.4. By Country
11. Asia Pacific CVD Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Class , 2015–2025
11.2.1. Renin-Angiotensin System Blockers
11.2.1.1. ACE Inhibitors
11.2.1.2. Angiotensin Receptor Blockers
11.2.2. Beta Blockers
11.2.3. Diuretics
11.2.4. Anti-Clotting Agents
11.2.4.1. Anti-Coagulants
11.2.4.2. Platelet Aggregation Inhibitors
11.2.5. Antihyperlipidemics
11.2.6. Other Antihypertensives
11.2.7. Calcium Channel Blockers
11.2.8. Others
11.3. Market Value Forecast By Indications , 2015–2025
11.3.1. Hypertension
11.3.2. Hyperlipidemia
11.3.3. Coronary Artery Disease
11.3.4. Peripheral Artery Disease
11.3.5. Arrhythmia
11.3.6. Others
11.4. Market Value Forecast By Distribution Channel , 2015–2025
11.4.1. Hospital Pharmacy
11.4.2. Retail Pharmacy
11.4.3. Online Pharmacy
11.5. Market Value Forecast By Country , 2015–2025
11.5.1. Japan
11.5.2. China
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Indications
11.6.3. By Distribution Channel
11.6.4. By Country
12. Latin America CVD Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Class , 2015–2025
12.2.1. Renin-Angiotensin System Blockers
12.2.1.1. ACE Inhibitors
12.2.1.2. Angiotensin Receptor Blockers
12.2.2. Beta Blockers
12.2.3. Diuretics
12.2.4. Anti-Clotting Agents
12.2.4.1. Anti-Coagulants
12.2.4.2. Platelet Aggregation Inhibitors
12.2.5. Antihyperlipidemics
12.2.6. Other Antihypertensives
12.2.7. Calcium Channel Blockers
12.2.8. Others
12.3. Market Value Forecast By Indications , 2015–2025
12.3.1. Hypertension
12.3.2. Hyperlipidemia
12.3.3. Coronary Artery Disease
12.3.4. Peripheral Artery Disease
12.3.5. Arrhythmia
12.3.6. Others
12.4. Market Value Forecast By Distribution Channel , 2015–2025
12.4.1. Hospital Pharmacy
12.4.2. Retail Pharmacy
12.4.3. Online Pharmacy
12.5. Market Value Forecast By Country , 2015–2025
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Indications
12.6.3. By Distribution Channel
12.6.4. By Country
13. Middle East & Africa CVD Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Class , 2015–2025
13.2.1. Renin-Angiotensin System Blockers
13.2.1.1. ACE Inhibitors
13.2.1.2. Angiotensin Receptor Blockers
13.2.2. Beta Blockers
13.2.3. Diuretics
13.2.4. Anti-Clotting Agents
13.2.4.1. Anti-Coagulants
13.2.4.2. Platelet Aggregation Inhibitors
13.2.5. Antihyperlipidemics
13.2.6. Other Antihypertensives
13.2.7. Calcium Channel Blockers
13.2.8. Others
13.3. Market Value Forecast By Indications , 2015–2025
13.3.1. Hypertension
13.3.2. Hyperlipidemia
13.3.3. Coronary Artery Disease
13.3.4. Peripheral Artery Disease
13.3.5. Arrhythmia
13.3.6. Others
13.4. Market Value Forecast By Distribution Channel , 2015–2025
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy
13.4.3. Online Pharmacy
13.5. Market Value Forecast By Country , 2015–2025
13.5.1. South Africa
13.5.2. GCC Region
13.5.3. Israel
13.5.4. Rest of Middle East and Africa
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Indications
13.6.3. By Distribution Channel
13.6.4. By Country
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis By Company (2016)
14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.3.1. AstraZeneca
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Pfizer Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Merck & Co. Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Bristol-Myers Squibb Company
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Bayer AG
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Sanofi
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Boehringer Ingelheim GmbH
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. F. Hoffmann-La Roche Ltd.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Abbott Laboratories
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Gilead Sciences, Inc.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Financial Overview
14.3.11.3. Product Portfolio
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
14.3.12. Johnson & Johnson
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Financial Overview
14.3.12.3. Product Portfolio
14.3.12.4. SWOT Analysis
14.3.12.5. Strategic Overview
14.3.13. Astellas Pharma, Inc.
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Financial Overview
14.3.13.3. Product Portfolio
14.3.13.4. SWOT Analysis
14.3.13.5. Strategic Overview
14.3.14. Eli Lilly and Company
14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.14.2. Financial Overview
14.3.14.3. Product Portfolio
14.3.14.4. SWOT Analysis
14.3.14.5. Strategic Overview
14.3.15. Otsuka Holdings Co., Ltd.
14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.15.2. Financial Overview
14.3.15.3. Product Portfolio
14.3.15.4. SWOT Analysis
14.3.15.5. Strategic Overview
14.3.16. Takeda Pharmaceuticals Company Limited
14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.16.2. Financial Overview
14.3.16.3. Product Portfolio
14.3.16.4. SWOT Analysis
14.3.16.5. Strategic Overview
List of Tables
Table 01: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 02: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class – Renin-Angiotensin System Blockers, 2015–2025
Table 03: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class – Anti-Clotting Agents, 2015–2025
Table 04: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 05: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 06: Global Cardiovascular Drugs Market Size (US$ Bn) Forecast, by Region, 2017–2025
Table 07: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 08: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 09: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
Table 10: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
Table 11: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 12: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 13: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 14: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 15: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
Table 16: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
Table 17: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 18: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 19: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 20: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 21: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
Table 22: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
Table 23: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 24: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 25: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 26: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 27: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
Table 28: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
Table 29: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 30: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 31: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 32: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 33: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
Table 34: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
Table 35: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 36: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 37: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
List of Figures
Figure 01: Global Cardiovascular Drugs Market Snapshot
Figure 02: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 03: Global Cardiovascular Market Value Share, by Drug Class (2016)
Figure 04: Global Cardiovascular Market Value Share, by Indication (2016)
Figure 05: Global Cardiovascular Market Value Share, by Distribution Channel (2016)
Figure 07: Global Cardiovascular Market Value Share, by Region (2016)
Figure 06: Global Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 08: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by RAS Blockers, 2015–2025
Figure 09: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Beta Blockers, 2015–2025
Figure 10: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Diuretics, 2015–2025
Figure 11: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Anti-clotting Agents, 2015–2025
Figure 12: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Antihyperlipidemics, 2015–2025
Figure 13: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Other Antihypertensive, 2015–2025
Figure 14: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Calcium Channel Blockers, 2015–2025
Figure 15: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2015–2025
Figure 16: Global Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class 2017-2025
Figure 17: Global Cardiovascular Drugs Market Value Share Analysis, by Indication, 2017 and 2025
Figure 18: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hypertension, 2015–2025
Figure 19: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hyperlipidemia, 2015–2025
Figure 20: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Coronary Artery Disease, 2015–2025
Figure 21: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Peripheral Vascular Disease, 2015–2025
Figure 22: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Antiarrhythmic, 2015–2025
Figure 23: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2015–2025
Figure 24: Global Cardiovascular Drugs Market Attractiveness Analysis, by Indication 2017-2025
Figure 25: Global Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 26: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
Figure 27: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2015–2025
Figure 28: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2015–2025
Figure 29: Global Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel 2017-2025
Figure 30: Global Cardiovascular Drugs Market Value Share Analysis, by Region, 2016 and 2025
Figure 31: Global Cardiovascular Drugs Market Attractiveness Analysis, by Region
Figure 32: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 33: North America Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
Figure 34: North America Cardiovascular Drugs Market Attractiveness Analysis, by Country
Figure 35: North America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 36: North America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
Figure 37: North America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 38: North America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
Figure 39: North America Cardiovascular Drugs Market Attractiveness Analysis, by Indication
Figure 40: North America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 41: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 42: Europe Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
Figure 43: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Country
Figure 44: Europe Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 45: Europe Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
Figure 46: Europe Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 47: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
Figure 48: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Indication
Figure 49: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 50: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 51: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
Figure 52: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Country
Figure 53: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 54: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
Figure 55: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 56: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
Figure 57: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Indication
Figure 58: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 59: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 60: Latin America Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
Figure 61: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Country
Figure 62: Latin America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 63: Latin America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
Figure 64: Latin America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 65: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
Figure 66: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Indication
Figure 67: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 68: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 69: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
Figure 70: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Country
Figure 71: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 72: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
Figure 73: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 74: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
Figure 75: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Indication
Figure 76: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 77: Global Cardiovascular Drugs Market Share Analysis By Company (2016)
Complete the form below and we'll get back to you shortly.
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
